Product/Composition:- | TAF + Emtricitabine + Rilpivirine |
---|---|
Strength:- | (TAF) – 25 mg + Emtricitabine – 200 mg + Rilpivirine – 25 mg |
Form:- | Tablet |
Reference Brands:- | Odefsey(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Odefsey is a once-daily HIV-1 treatment combining TAF, Emtricitabine, and Rilpivirine. FDA and EMA approved, it offers improved kidney and bone safety compared to TDF-based regimens and must be taken with food.
Odefsey is a once-daily, fixed-dose combination tablet containing Tenofovir Alafenamide (TAF) 25 mg, Emtricitabine 200 mg, and Rilpivirine 25 mg, used for the treatment of HIV-1 infection in virologically suppressed patients or treatment-naïve individuals without resistance to its components. Approved by the FDA and EMA, Odefsey is a TAF-based alternative to older TDF regimens like Complera/Eviplera, offering improved renal and bone safety. It is indicated for adults and adolescents (≥12 years and ≥35 kg) and must be taken with a meal. Odefsey simplifies therapy by combining three potent agents into a single-tablet regimen.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications